ATE549011T1 - Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten - Google Patents

Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten

Info

Publication number
ATE549011T1
ATE549011T1 AT05077559T AT05077559T ATE549011T1 AT E549011 T1 ATE549011 T1 AT E549011T1 AT 05077559 T AT05077559 T AT 05077559T AT 05077559 T AT05077559 T AT 05077559T AT E549011 T1 ATE549011 T1 AT E549011T1
Authority
AT
Austria
Prior art keywords
growth hormone
somatostatin analogue
sustained release
release formulations
formulations containing
Prior art date
Application number
AT05077559T
Other languages
English (en)
Inventor
Paolo Mascagni
Original Assignee
Chemi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemi Spa filed Critical Chemi Spa
Application granted granted Critical
Publication of ATE549011T1 publication Critical patent/ATE549011T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
AT05077559T 2005-11-10 2005-11-10 Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten ATE549011T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05077559A EP1787658B1 (de) 2005-11-10 2005-11-10 Formulierungen mit verzögerter Freisetzung, die Somatostatin-analoge Wachstumshormoninhibitoren enthalten

Publications (1)

Publication Number Publication Date
ATE549011T1 true ATE549011T1 (de) 2012-03-15

Family

ID=35840709

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05077559T ATE549011T1 (de) 2005-11-10 2005-11-10 Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten

Country Status (8)

Country Link
EP (1) EP1787658B1 (de)
AT (1) ATE549011T1 (de)
CY (1) CY1112857T1 (de)
DK (1) DK1787658T3 (de)
ES (1) ES2383303T3 (de)
PL (1) PL1787658T3 (de)
PT (1) PT1787658E (de)
SI (1) SI1787658T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
WO2009071460A2 (en) * 2007-12-03 2009-06-11 Italfarmaco Spa New non-selective somatostatin analogues
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045135A1 (de) 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
GB8318552D0 (en) 1983-07-08 1983-08-10 Sandoz Ltd Organic compounds
NL8701143A (nl) 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
GB2193891B (en) 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
NL194729C (nl) 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
DE3845000C2 (de) 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY108621A (en) 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
GB9206736D0 (en) 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
EP0671937A4 (de) 1992-10-16 1996-09-18 Smithkline Beecham Corp Pharmazeutische emulsionszusammensetzungen.
CA2161781A1 (en) 1993-06-22 1995-01-05 Thomas Kissel Surface-modified albumin microspheres and pharmaceutical compositions containing them
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
AU3257297A (en) 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
WO1999021533A2 (en) * 1997-10-24 1999-05-06 Neorx Corporation Delivery vehicles for bioactive agents and uses thereof
GB2331924A (en) 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
DK0988861T3 (da) * 1998-08-17 2004-04-19 Pfizer Prod Inc Stabiliserede proteinpræparater
US6159935A (en) 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
AU2001283957A1 (en) 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
EP1499361B1 (de) 2002-04-19 2012-08-08 Novartis AG Neue biomaterialien, deren herstellung und gebrauch
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
GB0228571D0 (en) 2002-12-06 2003-01-15 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CY1112857T1 (el) 2016-04-13
DK1787658T3 (da) 2012-06-25
SI1787658T1 (sl) 2012-07-31
EP1787658B1 (de) 2012-03-14
PL1787658T3 (pl) 2012-08-31
EP1787658A1 (de) 2007-05-23
ES2383303T3 (es) 2012-06-20
PT1787658E (pt) 2012-06-22

Similar Documents

Publication Publication Date Title
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
ATE216230T1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
UY25148A1 (es) Método para producir una composición farmacéutica que comprende un análogo de ácido gama aminobutírico (gaba) y una droga antiinflamatoria no esteroide (nsaid)
ATE279209T1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
JP2003534265A5 (de)
WO2003013497A1 (fr) Compositions s'averant efficaces pour prevenir ou soulager des troubles ou maladies provoques par une hypofonction cerebrale
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
ATE394365T1 (de) Verfahren zur synthese von verbindungen vom ceramidtyp
BR0209320A (pt) ésteres de uridina farmaceuticamente ativos
AR029615A1 (es) Una formulacion farmaceutica para la administracion oral
ES2147837T3 (es) Nuevos compuestos heterociclicos.
CY1112857T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης αναλογου σωματοστατινης αναστολεων αναπτυξης ορμονης
NO20055601L (no) Farmasoytisk preparat i form av en hydrogel for transdermal administrasjon av aktive virkestoffer
PE20040158A1 (es) Sales de nateglinida
GEP20053455B (en) Pharmaceutical Preparations
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AR029412A1 (es) Forma cristalina
WO2008093772A1 (ja) 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
FR2722410B1 (fr) Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
NO20024796L (no) Preparater for anvendelse som penetrasjonsfremmere i transdermale formuleringer for meget lipofile aktive bestanddeler
JP5048372B2 (ja) 育毛促進剤
AR051742A1 (es) Capsulas de lercanidipino
ATE462418T1 (de) Stabile pharmazeutische zubereitungen zur kontrollierten freisetzung von fenofibrat and pravastatin